Journal of Neurology

, Volume 258, Issue 11, pp 2100–2104 | Cite as

Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability

  • M. Maschio
  • L. Dinapoli
  • M. Mingoia
  • F. Sperati
  • A. Pace
  • A. Pompili
  • C. M. Carapella
  • A. Vidiri
  • P. Muti
Short Commentary


Lacosamide (LCM) is an antiepileptic drug (AED) that has demonstrated a good efficacy in controlling seizures as an add-on in adult epilepsy. To date, there have been no studies on LCM in patients with brain tumor-related epilepsy (BTRE). To evaluate efficacy and tolerability of LCM as an add-on in BTRE, we followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min < 1 max 10 months). Mean seizure number in the last month prior to the introduction of LCM had been 15.4. At last follow-up, the mean seizure number was reduced to 1.9/month. Lacosamide mean dosage was of 332.1 mg/day (min 100 max 400 mg/day). Responder rate was 78.6%. One patient discontinued LCM because of side-effects. There were no other reported side-effects. Preliminary data on the use of LCM in add-on in patients with BTRE indicate that this drug may represent a valid alternative as an add-on in this particular patient population. However, larger samples are necessary in order to draw definitive conclusions.


Antiepileptic drugs Brain tumor-related epilepsy Lacosamide 


  1. 1.
    van Breemen MSM, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519–1526PubMedCrossRefGoogle Scholar
  2. 2.
    Vecht CJ, Van Breemen M (2006) Optimizing therapy of seizures in patients with brain tumors. Neurology 67(12 Suppl 4):S10–S13PubMedGoogle Scholar
  3. 3.
    Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48:1308–1317PubMedCrossRefGoogle Scholar
  4. 4.
    Kelemen A, Halász P (2010) Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 6:465–471PubMedCrossRefGoogle Scholar
  5. 5.
    Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2009) Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 83:1–43PubMedCrossRefGoogle Scholar
  6. 6.
    Cross SA, Curran MP (2009) Lacosamide: in partial-onset seizures. Drugs 69:449–459PubMedCrossRefGoogle Scholar
  7. 7.
    Beydoun A, D’Souza J, Hebert D, Doty P (2009) Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 9:33–42PubMedCrossRefGoogle Scholar
  8. 8.
    Newton HB, Connelly J, Lima J, Cunningham H, Pearl D, Malkin M (2010) Lacosamide in brain tumour patients with refractory seizures: efficacy and tolerability. J Neurol 25(Suppl 1):S1–S246 P476Google Scholar
  9. 9.
    Fisher RS, van Emde Boas W, Blume W et al (2005) Epileptic seizures and epilepsy: definitions proposed by the International league against epilepsy (ILAE) and the International bureau for epilepsy (IBE). Epilepsia 46:470–482PubMedCrossRefGoogle Scholar
  10. 10.
    Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0, DCTD, NCI, NIH, DHHS, December 12, 2003.
  11. 11.
    Taillibert S, Laigle-Donadey F, Sanson M (2004) Palliative care in patients with primary brain tumors. Curr Opin Oncol 16:587–592PubMedCrossRefGoogle Scholar
  12. 12.
    Maschio M, Dinapoli L, Vidiri A et al (2009) The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 28:60PubMedCrossRefGoogle Scholar
  13. 13.
    Maschio M, Dinapoli L, Zarabla A et al (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 86:61–70PubMedCrossRefGoogle Scholar
  14. 14.
    Maschio M, Albani F, Baruzzi A et al (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100PubMedCrossRefGoogle Scholar
  15. 15.
    Novy J, Stupp R, Rossetti AO (2009) Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 111:171–173PubMedCrossRefGoogle Scholar
  16. 16.
    Maschio M, Dinapoli L, Saveriano F et al (2009) Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report. Acta Neurol Scand 120:210–212PubMedCrossRefGoogle Scholar
  17. 17.
    Pace A, Vidiri A, Galiè E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722–1726PubMedCrossRefGoogle Scholar
  18. 18.
    Ngo L, Nei M, Glass J (2006) Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia 47:1237–1238PubMedCrossRefGoogle Scholar
  19. 19.
    Maschio M, Dinapoli L, Sperati F et al (2010) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol Nov 25 [Epub ahead of print]Google Scholar
  20. 20.
    Dinapoli L, Maschio M, Jandolo B et al (2009) Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci May 5 [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. Maschio
    • 1
  • L. Dinapoli
    • 1
  • M. Mingoia
    • 1
  • F. Sperati
    • 3
  • A. Pace
    • 2
  • A. Pompili
    • 4
  • C. M. Carapella
    • 4
  • A. Vidiri
    • 5
  • P. Muti
    • 6
  1. 1.Center for Tumor-related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical-Facial PathologyNational Institute for Cancer “Regina Elena”RomeItaly
  2. 2.Neurology Unit, Department of Neuroscience and Cervical-Facial PathologyNational Institute for Cancer “Regina Elena”RomeItaly
  3. 3.Department of EpidemiologyNational Institute for Cancer “Regina Elena”RomeItaly
  4. 4.Division of Neurosurgery, Department of Neuroscience and Cervical-Facial PathologyNational Institute for Cancer “Regina Elena”RomeItaly
  5. 5.Department of RadiologyNational Institute for Cancer “Regina Elena”RomeItaly
  6. 6.Scientific Direction of National Institute for Cancer “Regina Elena”RomeItaly

Personalised recommendations